{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T23:48:49Z","timestamp":1763768929229,"version":"3.45.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research in Social and Administrative Pharmacy"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.sapharm.2025.08.004","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T15:21:58Z","timestamp":1754925718000},"page":"54-65","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Public, private, and out-of-pocket spending comparisons between respondents with and without opioids and the impact of the Comprehensive Addiction Recovery Act, 2008\u20132020: A serial cross-sectional study"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7343-9458","authenticated-orcid":false,"given":"Mark","family":"Bounthavong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aryana","family":"Sepassi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Britney","family":"Stottlemyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Spoutz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Hart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kangho","family":"Suh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.sapharm.2025.08.004_bib1","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13011-021-00415-5","article-title":"Trends in healthcare expenditures and resource utilization among a nationally representative population with opioids in the United States: a serial cross-sectional study, 2008 to 2017","volume":"16","author":"Bounthavong","year":"2021","journal-title":"Subst Abuse Treat Prev Pol"},{"key":"10.1016\/j.sapharm.2025.08.004_bib3","series-title":"Health and Economic Growth: Findings and Policy Implications. First","article-title":"On the health-poverty trap","author":"Sala-i-Martin","year":"2005"},{"key":"10.1016\/j.sapharm.2025.08.004_bib4","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1146\/annurev.soc.012809.102529","article-title":"Socioeconomic disparities in health behaviors","volume":"36","author":"Pampel","year":"2010","journal-title":"Annu Rev Sociol"},{"issue":"9","key":"10.1016\/j.sapharm.2025.08.004_bib5","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1136\/jech.57.9.711","article-title":"Income and health behaviours. Evidence from monitoring surveys among Finnish adults","volume":"57","author":"Laaksonen","year":"2003","journal-title":"J Epidemiol Community Health"},{"issue":"2","key":"10.1016\/j.sapharm.2025.08.004_bib6","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/EDE.0000000000000038","article-title":"Association among socioeconomic status, health behaviors, and all-cause mortality in the United States","volume":"25","author":"Nandi","year":"2014","journal-title":"Epidemiology"},{"issue":"5","key":"10.1016\/j.sapharm.2025.08.004_bib7","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1377\/hlthaff.2015.1103","article-title":"Payments for opioids shifted substantially to public and private insurers while consumer spending declined, 1999\u20132012","volume":"35","author":"Zhou","year":"2016","journal-title":"Health Aff"},{"issue":"1","key":"10.1016\/j.sapharm.2025.08.004_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.japh.2024.102299","article-title":"The effect of out-of-pocket costs on medications for opioid use disorder and overdose: a scoping review","volume":"65","author":"Watema-Lord","year":"2025","journal-title":"J Am Pharm Assoc"},{"year":"2022","series-title":"Comprehensive Addiction and Recovery Act (CARA) Local Drug Crises Program National Cross-Site Evaluation: Cohort 1 2021 Report","key":"10.1016\/j.sapharm.2025.08.004_bib10"},{"issue":"8","key":"10.1016\/j.sapharm.2025.08.004_bib11","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"147","author":"von Elm","year":"2007","journal-title":"Ann Intern Med"},{"year":"2019","series-title":"Sample Designs of the Medical Expenditure Panel Survey Household Component, 1996\u20132006 and 2007\u20132016. Methodology Report #33","author":"Chowdhury","key":"10.1016\/j.sapharm.2025.08.004_bib14"},{"issue":"165","key":"10.1016\/j.sapharm.2025.08.004_bib15","first-page":"1","article-title":"Design and estimation for the national health interview survey, 2006-2015","author":"Parsons","year":"2014","journal-title":"Vital Health Stat 2"},{"key":"10.1016\/j.sapharm.2025.08.004_bib16","first-page":"1","article-title":"Sample design and estimation structures for the national health interview survey, 2016-2025","volume":"191","author":"Moriarity","year":"2022","journal-title":"Vital Health Stat 1 Progr Collect Proced"},{"year":"2022","series-title":"MEPS HC-220A: 2020 Prescribed Medicine","key":"10.1016\/j.sapharm.2025.08.004_bib17"},{"issue":"3","key":"10.1016\/j.sapharm.2025.08.004_bib18","first-page":"242","article-title":"Implications of the accuracy of MEPS prescription drug data for health services research","volume":"48","author":"Hill","year":"2011","journal-title":"Inq J Med Care Organ Provis Financ"},{"year":"2019","series-title":"Medications for Opioid Use Disorder save Lives","key":"10.1016\/j.sapharm.2025.08.004_bib19"},{"issue":"1","key":"10.1016\/j.sapharm.2025.08.004_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-019-0137-5","article-title":"Opioid use disorder","volume":"6","author":"Strang","year":"2020","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"10.1016\/j.sapharm.2025.08.004_bib21","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1056\/NEJMra1604339","article-title":"Treatment of opioid-use disorders","volume":"375","author":"Schuckit","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.sapharm.2025.08.004_bib22","doi-asserted-by":"crossref","DOI":"10.1111\/j.1468-0009.2005.00428.x","article-title":"Societal and individual determinants of medical care utilization in the United States","volume":"83","author":"Andersen","year":"2005","journal-title":"Milbank Q"},{"author":"Kirby","key":"10.1016\/j.sapharm.2025.08.004_bib24"},{"author":"Machlin","key":"10.1016\/j.sapharm.2025.08.004_bib26"},{"issue":"1","key":"10.1016\/j.sapharm.2025.08.004_bib29","doi-asserted-by":"crossref","DOI":"10.21037\/atm.2018.12.10","article-title":"Balance diagnostics after propensity score matching","volume":"7","author":"Zhang","year":"2019","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.sapharm.2025.08.004_bib30","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jmp.2016.08.004","article-title":"Evaluating the model fit of diffusion models with the root mean square error of approximation","volume":"77","author":"Schubert","year":"2017","journal-title":"J Math Psychol"},{"issue":"8","key":"10.1016\/j.sapharm.2025.08.004_bib31","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2022.2663","article-title":"Trends in out-of-pocket costs for naloxone by drug brand and payer in the US, 2010-2018","volume":"3","author":"Peet","year":"2022","journal-title":"JAMA Health Forum"},{"issue":"2","key":"10.1016\/j.sapharm.2025.08.004_bib32","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.54590","article-title":"Trends in out-of-pocket costs for and characteristics of pharmacy-dispensed buprenorphine medications for opioid use disorder treatment by type of payer, 2015 to 2020","volume":"6","author":"Strahan","year":"2023","journal-title":"JAMA Netw Open"},{"author":"Saunders","key":"10.1016\/j.sapharm.2025.08.004_bib33"},{"issue":"3","key":"10.1016\/j.sapharm.2025.08.004_bib34","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.0242","article-title":"Assessment of annual cost of substance use disorder in US hospitals","volume":"4","author":"Peterson","year":"2021","journal-title":"JAMA Netw Open"},{"year":"2023","series-title":"Drug Overdose Death Rates","key":"10.1016\/j.sapharm.2025.08.004_bib35"},{"key":"10.1016\/j.sapharm.2025.08.004_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108645","article-title":"Users of retail medications for opioid use disorders faced high out-of-pocket prescription spending in 2011-2017","volume":"132","author":"McClellan","year":"2022","journal-title":"J Subst Abuse Treat"},{"key":"10.1016\/j.sapharm.2025.08.004_bib37","doi-asserted-by":"crossref","unstructured":"Basu A, Veenstra DL, Devine B, Carlson JJ, Sullivan SD. Medicare drug price negotiations: a principles-based guide for CMS. Health Aff Forefr. doi:10.1377\/forefront.20230620.965471.","DOI":"10.1377\/forefront.20230620.965471"},{"issue":"5 Pt 1","key":"10.1016\/j.sapharm.2025.08.004_bib39","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1111\/j.1475-6773.2009.00995.x","article-title":"Validating household reports of health care use in the medical expenditure panel survey","volume":"44","author":"Zuvekas","year":"2009","journal-title":"Health Serv Res"},{"issue":"1","key":"10.1016\/j.sapharm.2025.08.004_bib40","first-page":"92","article-title":"Accuracy of medicare expenditures in the medical expenditure panel survey","volume":"46","author":"Zuvekas","year":"2009","journal-title":"Inq J Med Care Organ Provis Financ"},{"key":"10.1016\/j.sapharm.2025.08.004_bib41","doi-asserted-by":"crossref","unstructured":"Berk M, Wilensky GR. How to make the medical expenditures panel survey Even more useful. Health Aff Forefr. doi:10.1377\/forefront.20161102.057386.","DOI":"10.1377\/forefront.20161102.057386"},{"year":"2010","series-title":"Econometric Analysis of Cross Section and Panel Data","author":"Wooldridge","key":"10.1016\/j.sapharm.2025.08.004_bib42"},{"key":"10.1016\/j.sapharm.2025.08.004_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108350","article-title":"The economic burden of opioid use disorder and fatal opioid overdose in the United States, 2017","volume":"218","author":"Florence","year":"2021","journal-title":"Drug Alcohol Depend"}],"container-title":["Research in Social and Administrative Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155174112500422X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155174112500422X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T23:43:51Z","timestamp":1763768631000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155174112500422X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S155174112500422X"],"URL":"https:\/\/doi.org\/10.1016\/j.sapharm.2025.08.004","relation":{},"ISSN":["1551-7411"],"issn-type":[{"type":"print","value":"1551-7411"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Public, private, and out-of-pocket spending comparisons between respondents with and without opioids and the impact of the Comprehensive Addiction Recovery Act, 2008\u20132020: A serial cross-sectional study","name":"articletitle","label":"Article Title"},{"value":"Research in Social and Administrative Pharmacy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.sapharm.2025.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}